

Freedom of Information Request	FOI 22-354	23 <sup>rd</sup> August 2022
--------------------------------	------------	------------------------------

**I have a freedom of information request and I would greatly appreciate if you could answer the following questions.**

**Q1. How many patients were treated in the last 12 months (for any disease) with:**

- Ethambutol + rifampicin + Clarithromycin/azithromycin**
- Ethambutol + rifampicin + Clarithromycin/azithromycin with the addition of injectable (IV) or nebulised Amikacin**

Please find below the quantities dispensed from the Health Board pharmacies for the period August 2021 – July 2022 for any condition.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Type	Quantity
AMIKACIN 100 mg in 2mL Injection 5 Vial Pack	5
AMIKACIN 500 mg in 2mL Injection 5 Vial Pack	190
AZITHROMYCIN 200 mg in 5mL Oral Liquid 15 mL Bottle	147
AZITHROMYCIN 200 mg in 5mL Oral Liquid 15 mL Pre-Pack	211
AZITHROMYCIN 200 mg in 5mL Oral Liquid 30 mL Bottle	16
AZITHROMYCIN 250 mg Capsules 4 Capsule Pack	44
AZITHROMYCIN 250 mg Tablets 4 Tablet Pack	245
AZITHROMYCIN 250 mg Tablets 4 Tablet Pre-Pack	551
AZITHROMYCIN 500 mg Intravenous Infusion 1 Vial Pack	21
AZITHROMYCIN 500 mg Tablets 3 Tablet Pack	70
AZITHROMYCIN 500 mg Tablets 4 Tablet Pre-Pack	39
CLARITHROMYCIN 125 mg in 5mL Oral Liquid 70 mL Bottle	42
CLARITHROMYCIN 125 mg in 5mL Oral Liquid 70 mL Pre-Pack	20
CLARITHROMYCIN 250 mg in 5mL Oral Liquid 70 mL Bottle	332
CLARITHROMYCIN 250 mg in 5mL Oral Liquid 70 mL Pre-Pack	4
CLARITHROMYCIN 500 mg Intravenous Infusion 10 Vial Pack	698
CLARITHROMYCIN 500 mg Tablets 14 Tablet Pack	559
CLARITHROMYCIN 500 mg Tablets 14 Tablet Pre-Pack	1677
ETHAMBUTOL HYDROCHLORIDE 100 mg Tablets 56 Tablet Pack	22
ETHAMBUTOL HYDROCHLORIDE 400 mg Tablets 56 Tablet Pack	26
RIFAMPICIN 100 mg in 5mL Oral Liquid 120 mL Bottle	33
RIFAMPICIN 100 mg in 5mL Oral Liquid 120 mL Pre-Pack	17
RIFAMPICIN 150 mg Capsules 100 Capsule Pack	31

Type	Quantity
RIFAMPICIN 150mg / ISONIAZID 100mg Tablets 84 Tablet Pack	2
RIFAMPICIN 300 mg Capsules 100 Capsule Pack	75
RIFAMPICIN 300 mg Capsules 60 Capsule Pack	10
RIFAMPICIN 600 mg Intravenous Infusion 1 Vial Pack	392

**Q2. How many patients have been diagnosed in the last 12 months for the following diseases?**

**a) Non-tuberculosis mycobacterium (NTM) (ICD10 codes: A31.0/A31.9)**

Inpatients	<5
Outpatients	19

Where less than five (5) patients have been identified, Section 40 of the Freedom of Information Act 2000 has been applied as the Health Board cannot provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**b) Bronchiectasis (ICD10 codes J47/Q33.4)**

Inpatients	759
Outpatients	321

Please note the figures provided are for the number of patients who have been treated by the Health Board as an outpatient or inpatient during the financial year 2021/22 and have had their condition clinically coded as a primary or secondary diagnosis. The Health Board can only identify those patients who have been treated for the condition and NOT when the patients were first diagnosed.

**Q3. Which other hospital trust or health care professional would you contact if you require advice on non-tuberculosis mycobacterium (NTM) infections?**

Representatives from the Health Board attend a quarterly All Wales NTM MDT which we discuss difficult NTM-PD cases.

**Q4. Do you discuss difficult to manage non-tuberculosis mycobacterium (NTM) patients as a Multidisciplinary Team (MDT)?**

Please refer to Q3.